Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Non Operating Income (2023 - 2025)

CG Oncology's Non Operating Income history spans 3 years, with the latest figure at $29.9 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 497866.67% year-over-year to $29.9 million; the TTM value through Dec 2025 reached $37.1 million, up 150.02%, while the annual FY2025 figure was $29.8 million, 992533.33% up from the prior year.
  • Non Operating Income reached $29.9 million in Q4 2025 per CGON's latest filing, up from -$100000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $29.9 million in Q4 2025 to a low of -$100000.0 in Q3 2025.
  • Average Non Operating Income over 3 years is $4.8 million, with a median of $1.7 million recorded in 2023.
  • The largest YoY upside for Non Operating Income was 497866.67% in 2025 against a maximum downside of 101.27% in 2025.
  • A 3-year view of Non Operating Income shows it stood at $2.8 million in 2023, then plummeted by 99.79% to $6000.0 in 2024, then surged by 497866.67% to $29.9 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Non Operating Income are $29.9 million (Q4 2025), -$100000.0 (Q3 2025), and $7.3 million (Q2 2025).